Sanofi Oncology Strategy: A New Lease On Cancer R&D

After failing to transition its cancer portfolio from chemotherapy to targeted cancer drugs, Sanofi is recharging its cancer strategy, relying on a collaboration with Regeneron Pharmaceuticals Inc. to vault it into the hot field of immuno-oncology.